Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 4/20 | 0.52 |
| ▸ | PLK1 | P53350 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 4/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.38 |
| ▸ | AURKA | O14965 | 2/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15328640 | 1.00 | SLC40A1 (0.52) | SLC40A1PLK1L3MBTL1KDM4EPSMD14 | |
| Hydrochloric Acid SCHEMBL28016092 | 0.99 | SLC40A1 (0.51) | SLC40A1PLK1L3MBTL1KDM4EPSMD14 | |
| Hydrochloric Acid SCHEMBL28016091 | 0.99 | SLC40A1 (0.51) | SLC40A1PLK1L3MBTL1KDM4EPSMD14 | |
| Hydrochloric Acid SCHEMBL29624025 | 0.99 | SLC40A1 (0.51) | SLC40A1PLK1L3MBTL1KDM4EPSMD14 | |
| Hydrochloric Acid SCHEMBL28552491 | 0.99 | SLC40A1 (0.51) | SLC40A1PLK1L3MBTL1KDM4EPSMD14 | |
| Trifluoroacetic Acid SCHEMBL28575034 | 0.92 | SLC40A1 (0.48) | SLC40A1PLK1L3MBTL1KDM4EPSMD14 | |
| SCHEMBL19905328 | 0.89 | SLC40A1 (0.53) | SLC40A1PLK1L3MBTL1KDM4EPSMD14 | |
| SCHEMBL19905064 | 0.86 | SLC40A1 (0.51) | SLC40A1PLK1L3MBTL1KDM4EPSMD14 | |
| SCHEMBL15343062 | 0.85 | SLC40A1 (0.54) | SLC40A1PLK1L3MBTL1KDM4EPSMD14 | |
| SCHEMBL18317971 | 0.85 | SLC40A1 (0.50) | SLC40A1PLK1L3MBTL1KDM4EPSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574211-B | Heterocyclic kinase inhibitors | 山东轩竹医药科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-112574179-B | DNA-PK inhibitors | 山东轩竹医药科技有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-11021465-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021465-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-01 | — | — | US | disclosed |
| US-11008305-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008305-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| CN-112574179-A | DNA-PK inhibitors | 山东轩竹医药科技有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-112574211-A | Heterocyclic kinase inhibitors | 山东轩竹医药科技有限公司 | 2021-03-30 | — | — | CN | disclosed |
| EP-3459942-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-12-30 | — | — | EP | disclosed |
| CN-106977495-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20150111871-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-23 | — | — | US | disclosed |
| EP-2841428-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20140045869-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| US-20140045869-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| US-20140045869-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| WO-2013163190-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013163190-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045869-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | SLC40A1 4477/4885PLK1 53/4885L3MBTL1 2098/4885 |
| US-11008305-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | SLC40A1 4477/4885PLK1 53/4885L3MBTL1 2098/4885 |
| US-20150111871-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | SLC40A1 4477/4885PLK1 53/4885L3MBTL1 2098/4885 |
| US-20130281431-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | SLC40A1 4477/4885PLK1 53/4885L3MBTL1 2098/4885 |
| US-11021465-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | SLC40A1 4477/4885PLK1 53/4885L3MBTL1 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.